Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > May 8, 2020
Daily News
May 8, 2020
- Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
- Daiichi Sankyo Seeks Gastric Cancer Use for Enhertu
May 8, 2020
- Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
- Sales Rep Promotions Decrease 34%, Seminars Down 84%: Intage
May 8, 2020
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
- Takeda to Maintain Partial Voluntary Ban on Sales Reps Activities in Japan amid Coronavirus Woes
May 8, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…